ADMA Biologics Accounts Payables 2011-2026 | ADMA

Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.

Main types of accounts payable

Type of liability	Example
To suppliers and contractors	Goods received but not yet paid for
Taxes and fees	VAT, income tax, etc., not paid on time
Salaries	Employee wages not paid
To budgets	Insurance contributions to funds not paid
To founders	Founders provided borrowed funds
To banks	Overdue loan payments
Other	Fines, penalties, forfeits, customer prepayments, etc.

Impact on the company's financial performance

Liquidity and solvency
Accounts payable are part of short-term liabilities, so they affect liquidity ratios
Financial stability
The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence
Capital turnover
Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals)
Risks and reputation
Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated

Annual Accounts Payables ADMA Biologics

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
22.5 M	20.2 M	15.7 M	13.2 M	12.4 M	11.1 M	9.17 M	5.9 M	5.92 M	2.56 M	2.09 M	1.78 M	2.71 M	1.06 M	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
22.5 M	1.06 M	9.02 M

Quarterly Accounts Payables ADMA Biologics

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
24 M	29.8 M	20.6 M	20.2 M	16 M	14.2 M	17.2 M	15.7 M	10.9 M	12.1 M	13 M	13.2 M	25.2 M	11.4 M	14.1 M	12.4 M	17.3 M	6.17 M	12.2 M	11.1 M	11.1 M	11.1 M	11.1 M	9.17 M	9.17 M	9.17 M	9.17 M	5.9 M	5.9 M	5.9 M	5.9 M	5.92 M	5.92 M	5.92 M	5.92 M	2.56 M	2.56 M	2.56 M	2.56 M	2.09 M	2.09 M	2.09 M	2.09 M	1.78 M	1.78 M	1.78 M	1.78 M	2.71 M	2.71 M	2.71 M	2.71 M	1.06 M	1.06 M	1.06 M	1.06 M	1.3 M	1.3 M	1.3 M	1.3 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
29.8 M	1.06 M	8.13 M

Accounts Payables of other stocks in the Biotechnology industry

Issuer	Accounts Payables	Price	% 24h	Market Cap	Country
Amphastar Pharmaceuticals AMPH	32.6 M	$ 21.87	2.15 %	$ 1.02 B	USA
I-Mab IMAB	570 M	-	-	$ 866 M	China
Aeglea BioTherapeutics AGLE	677 K	-	-	$ 1.01 B	USA
Aptorum Group Limited APM	3.24 M	$ 0.9	-	$ 6.62 M	China
ACADIA Pharmaceuticals ACAD	16.2 M	$ 22.28	1.46 %	$ 3.69 B	USA
Advaxis ADXS	6.08 M	-	-9.65 %	$ 45.9 M	USA
AIkido Pharma AIKI	611 K	-	1.93 %	$ 17.4 M	USA
Akouos AKUS	1.28 M	-	0.23 %	$ 488 M	USA
Allakos ALLK	1.76 M	-	-	$ 28.6 M	USA
AlloVir ALVR	1.28 M	-	4.14 %	$ 49.1 M	USA
Ampio Pharmaceuticals AMPE	750 K	-	-11.43 %	$ 502 K	USA
Applied Molecular Transport AMTI	1.58 M	-	-	$ 10.1 M	USA
Brainstorm Cell Therapeutics BCLI	7.07 M	-	-2.5 %	$ 5.88 M	USA
Applied Therapeutics APLT	1.74 M	-	-	$ 8.42 M	USA
Aptinyx APTX	724 K	-	-39.0 %	$ 4.57 M	USA
AgeX Therapeutics AGE	1.93 M	-	-10.17 %	$ 12.2 K	USA
Aravive ARAV	8.76 M	-	-13.39 %	$ 1.45 M	USA
Aridis Pharmaceuticals ARDS	2.31 M	-	17.91 %	$ 11.1 M	USA
Avenue Therapeutics ATXI	78 K	-	-52.27 %	$ 4.45 M	USA
Applied Genetic Technologies Corporation AGTC	2.91 M	-	-	$ 26.5 M	USA
Aquestive Therapeutics AQST	29.9 M	$ 4.1	0.37 %	$ 438 M	USA
Arcutis Biotherapeutics ARQT	12.5 M	$ 23.98	3.07 %	$ 3.05 B	USA
Ayala Pharmaceuticals AYLA	4.08 M	-	-	$ 7.46 M	Israel
Autolus Therapeutics plc AUTL	3.08 M	$ 1.47	1.74 %	$ 391 M	Britain
Aptose Biosciences APTO	2.91 M	-	-45.71 %	$ 1.2 M	Canada
AVROBIO AVRO	27 K	-	1083.1 %	$ 745 M	USA
Can-Fite BioPharma Ltd. CANF	561 K	$ 2.98	2.41 %	$ 4.91 M	Israel
BioDelivery Sciences International BDSI	8.11 M	-	-4.8 %	$ 255 M	USA
BeiGene, Ltd. BGNE	479 M	-	0.49 %	$ 251 B	Cayman-islands
Akero Therapeutics AKRO	9.03 M	-	-	$ 3.67 B	USA
bluebird bio BLUE	18.5 M	-	-	$ 546 M	USA
ContraFect Corporation CFRX	13.7 M	-	-5.16 %	$ 5.39 M	USA
Cardiff Oncology CRDF	8.09 M	$ 1.72	-	$ 115 M	USA
BioXcel Therapeutics BTAI	14.7 M	$ 1.1	3.76 %	$ 13.4 M	USA
Cabaletta Bio CABA	6.64 M	$ 2.97	0.68 %	$ 298 M	USA
Cara Therapeutics CARA	3.22 M	-	-3.03 %	$ 260 M	USA
Allena Pharmaceuticals ALNA	1.03 M	-	3.16 %	$ 1.9 M	USA
CASI Pharmaceuticals CASI	4.79 M	-	-	$ 35.4 M	USA
CymaBay Therapeutics CBAY	3.83 M	-	-	$ 3.45 B	USA